A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine

Study Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study With an Open-Label Treatment Period of Fremanezumab Administered Subcutaneously Monthly or Quarterly for the Preventive Treatment of Migraine in Adult Chinese Patients
Teva Identifier
TV48125-CNS-30088
ClinicalTrials.gov Identifier
NCT05458011
Study Status
Completed
Trial Condition(s)
Migraine Headache
Interventions
Drug: Fremanezumab | Drug: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
headache-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years to 70 Years
Trial Duration
September 30, 2022 - June 13, 2024
Phase
Phase 3

Study Type

Interventional